RBx 4638

Drug Profile

RBx 4638

Alternative Names: Clafrinast

Latest Information Update: 20 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ranbaxy Laboratories
  • Class Antiasthmatics
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 04 Dec 2002 No development reported - Preclinical for Asthma in India (PO)
  • 11 Apr 2000 ClafrinastTM is available for licensing (http://www.ranbaxy.com/)
  • 11 Apr 2000 Preclinical development for Asthma in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top